Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atirmociclib PK Dose Proportionality in Healthy Participants Under Fed Conditions
NCT07215078Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atirmociclib (6 cohorts), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time at 120 hours and Maximum Observed Plasma Concentration at 120 hours. Started Oct 2025; status: completed.
02
Drugs
atirmociclib
Beyond the preview
Go deeper on NCT07215078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215078.